Background and aims: Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists, primarily used for treating diabetes, have recently demonstrated neuroprotective properties in a mouse model for Parkinson's disease (PD). Here, GLP1R is linked to Parkinson disease.